Amalgamated Financial’s Akero Therapeutics AKRO Stock Holding History

Amalgamated Financial’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$56K	Buy	+3,919	New	+$68.6K	﹤0.01%	2370

Other funds holding AKRO

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

YCM

Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return

Amalgamated Financial's AKRO Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Akero Therapeutics (AKRO) in Q1 2022: 3,919 shares worth $56K. The stake represents ﹤0.01% of the portfolio and ranks #2370 among its holdings.

103 funds tracked by Wall St. Rank hold AKRO as of Q1 2022.

Amalgamated Financial held 3,919 shares of Akero Therapeutics worth $56K as of Q1 2022.
Akero Therapeutics was a new Amalgamated Financial position in Q1 2022.
Akero Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2370 holding.
103 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.